Skip to Content

Tenet Healthcare Corp

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Tenet Earnings: Strong Facility Utilization Trends Boost 2023 Outlook Again

Tenet reported robust third-quarter results that were roughly in line with our expectations. Our $95 fair value estimate remains intact, and following an over 30% decline in Tenet’s stock price since early September, shares look attractive to us. Positively, management raised its 2023 adjusted EBITDA outlook for a third time this year to between $3.365 billion and $3.465 billion related to strong facility utilization trends as well as effective cost controls. Despite our no-moat rating, we recognize Tenet’s leadership in the high-margin, fast-growing ambulatory care market, and we continue to forecast that Tenet’s return on invested capital will stay above its capital costs over the next five years.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of THC so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center